Actinium Pharmaceuticals (NYSE:ATNM) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a report released on Friday morning,Benzinga reports. They currently have a $4.00 price objective on the stock.

ATNM has been the topic of a number of other research reports. StockNews.com cut Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. B. Riley lowered Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $16.00 to $2.00 in a research note on Wednesday, August 7th. Finally, Maxim Group lowered their target price on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Actinium Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $11.40.

Actinium Pharmaceuticals Price Performance

Shares of ATNM stock traded down $0.15 during trading hours on Friday, reaching $1.50. 631,169 shares of the stock were exchanged, compared to its average volume of 446,255. The company has a market cap of $46.79 million, a price-to-earnings ratio of -0.99 and a beta of 0.14. Actinium Pharmaceuticals has a 12-month low of $1.33 and a 12-month high of $10.24. The stock’s 50-day moving average is $1.79.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several large investors have recently modified their holdings of ATNM. Los Angeles Capital Management LLC bought a new position in Actinium Pharmaceuticals in the third quarter worth approximately $322,000. XTX Topco Ltd purchased a new stake in shares of Actinium Pharmaceuticals during the 3rd quarter worth $268,000. Marshall Wace LLP boosted its position in Actinium Pharmaceuticals by 67.9% during the second quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock valued at $1,895,000 after purchasing an additional 103,557 shares in the last quarter. Vanguard Group Inc. grew its stake in Actinium Pharmaceuticals by 6.0% in the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after purchasing an additional 82,113 shares during the last quarter. Finally, Virtu Financial LLC raised its holdings in Actinium Pharmaceuticals by 319.2% in the first quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock worth $642,000 after purchasing an additional 62,459 shares in the last quarter. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).